Current applications of tumor local ablation(TLA)combined with immune checkpoint inhibitors in breast cancer treatment  

作　　者：Lingpeng Tang Dandan Wang Ting Hu Xiaoying Lin Songsong Wu 

机构地区：[1]Department of Ultrasonography,Shengli Clinical Medical College of Fujian Medical University,Fujian Provincial Hospital,Fuzhou University Affiliated Provincial Hospital,Fuzhou 350001,Fujian,China [2]Department of Ultrasound,The Second Affiliated Hospital of Fujian Medical University,Quanzhou 362000,Fujian,China

出　　处：《Cancer Drug Resistance》2024年第1期439-458,共20页癌症耐药(英文)

基　　金：supported by the Fujian Science and Technology Innovation Joint Funding Program(No.2023Y9332).

摘　　要：Breast cancer is one of the most common cancers in women globally,posing significant challenges to treatment because of the diverse and complex pathological and molecular subtypes.The emergence of immune checkpoint inhibitors(ICIs)has revolutionized the treatment of breast cancer,particularly for triple-negative breast cancer(TNBC),significantly improving patient outcomes.However,the overall tumor response rate remains suboptimal due to drug resistance to ICIs.This resistance is primarily due to the immune-suppressive tumor microenvironment(TME),tumor cells’ability to evade immune surveillance,and other complex immune regulatory mechanisms.To address these challenges,clinical researchers are actively exploring combinatorial therapeutic strategies with ICIs.Tumor local ablation(TLA)technology is anticipated to overcome resistance to ICIs and enhance therapeutic efficacy by ablating tumor tissue,releasing tumor antigens,remodeling the TME,and stimulating local and systemic immune responses.Combination therapy with TLA and ICIs has demonstrated promising results in preclinical breast cancer studies,underscoring the feasibility and importance of addressing drug resistance mechanisms in breast cancer.This provides novel strategies for breast cancer treatment and is expected to drive further advancements in the field.

关 键 词：Tumor microenvironment antitumor immune response ablation immune checkpoint inhibitors 

分 类 号：R73[医药卫生—肿瘤]